Understanding exercise intolerance in patients with non-obstructive hypertrophic cardiomyopathy
Official title: Exercise Intolerance in Non Obstructive Hypertrophic Cardiomyopathy
Funded at University of California, San Francisco · NIH-11045757 · Data updated 2026-11-12
This study is looking at how exercise affects people with non-obstructive hypertrophic cardiomyopathy (HCM) and aims to find out if exercise training can help improve heart function and make it easier for them to be active, ultimately enhancing their quality of life.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | May 1, 2022 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $726,745 |
| NIH project number | 5R01HL157238-04 |
| Project ID | NIH-11045757 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with non-obstructive hypertrophic cardiomyopathy who experience exercise intolerance.
✕Less likely to help
Patients with obstructive hypertrophic cardiomyopathy or those without exercise intolerance may not benefit from this research.
What this research studies
This research investigates how exercise intolerance affects patients with non-obstructive hypertrophic cardiomyopathy (HCM), a common genetic heart disease. The study aims to explore the relationship between myocardial mechanics, microvascular ischemia, and exercise capacity in these patients. By utilizing advanced imaging techniques like PET and CMR, researchers will assess how exercise training may improve heart function and overall exercise tolerance. The goal is to identify effective therapeutic strategies that could enhance the quality of life for individuals with this condition.
Why it matters
Potential benefit: If successful, this research could lead to new exercise-based therapies that significantly improve the exercise capacity and quality of life for patients with non-obstructive HCM.
How similar studies have gone: Previous research has shown promising results in understanding exercise capacity in HCM, but this specific focus on non-obstructive cases is relatively novel.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Abraham, Theodore P — University of California, San Francisco
- Study coordinator: Abraham, Theodore P
Related research
Other NIH-funded projects on the same topics.
-
SGLT inhibitors for non-obstructive hypertrophic cardiomyopathy
A testing of a diabetes drug class (SGLT2 inhibitors) to help people with non-obstructive hypertrophic cardiomyopathy feel better and reduce heart-related problems.
-
Using big biobanks to understand rare gene changes in hypertrophic cardiomyopathy
A large study will look at genetic data and health information from many people to better understand how rare gene changes influence hypertrophic cardiomyopathy and its risks.
-
Understanding heart disease in hypertrophic cardiomyopathy through heart tissue and blood analysis
Researchers are studying people with hypertrophic cardiomyopathy to see how genes and signaling in heart tissue and blood relate to disease progression and risk of serious heart problems.
-
Myosin binding protein C variants and heart disease
A doctor-scientist at the University of Michigan is studying how certain genetic changes in a heart protein (MYBPC3) cause hypertrophic cardiomyopathy and whether fixing the protein or its interactions could help people with this condition.
-
MEK inhibitor for severe infantile heart failure in Noonan and related RASopathies
A 12-month, multi-site trial tests whether the medicine trametinib can help infants with life-threatening heart failure due to Noonan syndrome and related genetic conditions.
-
MEK inhibitor shows promise for serious infant heart disease in Noonan/RASopathies
A multi-site study tests whether the drug trametinib can help infants with severe heart muscle thickening caused by Noonan syndrome and related RASopathies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.